VOR

+ Watchlist + Portfolio

Vor Biopharma Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $18.06
52-Week Range: $6.50 – $38.31
Market Cap: $1.01B
P/E (TTM): 0.10
EPS (TTM): 180.18
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -21.37%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 19.15
Debt/Equity: —
Total Debt: $2.88M
Free Cash Flow: $-79.50M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $642.49M

VOR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$64.55M	$94.31M	$93.31M	$321.53M
Selling, General & Admin	$28.87M	$31.72M	$27.88M	$50.11M
Operating Expenses	$93.42M	$126.04M	$121.19M	$371.64M
Operating Income	-$93.42M	-$126.04M	-$121.19M	-$371.64M
EBITDA	-$90.89M	-$122.54M	-$117.66M	-$368.75M
Pretax Income	-$92.09M	-$117.86M	-$116.91M	-$695.98M
Net Income	-$92.09M	-$117.86M	-$116.91M	-$695.98M
Diluted EPS	-46.60	-35.00	-34.03	-70.50
Diluted Shares	1.98M	3.36M	3.44M	9.87M

VOR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$57.71M	$31.36M	$81.95M	$396.49M
Current Assets	$236.95M	$140.80M	$96.51M	$458.11M
Total Assets	$299.37M	$198.13M	$142.89M	$464.13M
Current Liabilities	$13.12M	$15.57M	$18.61M	$25.17M
Total Debt	$38.91M	$35.66M	$31.83M	$3.00M
Total Liabilities	$48.76M	$47.40M	$46.23M	$628.44M
Retained Earnings	-$222.22M	-$340.08M	-$456.99M	-$1.15B
Shareholders' Equity	$250.61M	$150.72M	$96.66M	-$164.31M
Working Capital	$223.83M	$125.23M	$77.89M	$432.93M

VOR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$85.14M	-$100.29M	-$99.66M	-$142.71M
Capital Expenditure	-$8.46M	-$1.07M	-$229.00K	-$941.00K
Free Cash Flow	-$93.61M	-$101.36M	-$99.89M	-$143.65M
Depreciation & Amortisation	$2.52M	$3.49M	$3.53M	$2.89M
Stock-Based Compensation	$10.70M	$13.36M	$9.85M	$18.91M
Investing Cash Flow	-$94.09M	$71.01M	$96.86M	-$48.80M
Financing Cash Flow	$117.14M	$2.94M	$53.39M	$503.81M
Net Change in Cash	-$62.09M	-$26.35M	$50.59M	$312.29M

VOR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$26.70M	$261.50M	$14.14M	$19.19M	$17.59M	$25.92M
Selling, General & Admin	$6.59M	$12.79M	$13.96M	$16.77M	$17.57M	$21.93M
Operating Expenses	$33.29M	$274.28M	$28.11M	$35.96M	$35.16M	$47.85M
Operating Income	-$33.29M	-$274.28M	-$28.11M	-$35.96M	-$35.16M	-$47.85M
EBITDA	-$32.47M	-$272.25M	-$28.11M	-$35.94M	-$35.13M	-$47.82M
Pretax Income	-$32.49M	-$1.57B	-$812.68M	$1.72B	-$219.59M	-$62.81M
Net Income	-$32.49M	-$1.57B	-$812.68M	$1.72B	-$219.59M	-$62.81M
Diluted EPS	-5.21	-251.24	-121.63	—	-5.11	-1.16
Diluted Shares	6.24M	6.26M	6.68M	—	43.01M	54.30M

VOR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$50.05M	$190.57M	$160.46M	$396.49M	$169.87M	$107.86M
Current Assets	$64.85M	$204.93M	$172.49M	$458.11M	$500.78M	$475.11M
Total Assets	$109.31M	$205.37M	$176.24M	$464.13M	$506.75M	$481.05M
Current Liabilities	$16.73M	$58.77M	$18.84M	$25.17M	$16.08M	$24.81M
Total Debt	$30.78M	$0.00	$3.06M	$3.00M	$2.94M	$2.88M
Total Liabilities	$43.24M	$1.71B	$2.40B	$628.44M	$657.17M	$681.25M
Retained Earnings	-$489.48M	-$2.06B	-$2.88B	-$1.15B	-$1.37B	-$1.44B
Shareholders' Equity	$66.07M	-$1.51B	-$2.23B	-$164.31M	-$150.42M	-$200.20M
Working Capital	$48.12M	$146.15M	$153.65M	$432.93M	$484.70M	$450.29M

VOR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$31.07M	-$35.18M	-$53.66M	-$22.80M	-$38.25M	-$25.38M
Capital Expenditure	-$231.00K	-$152.00K	-$244.00K	-$314.00K	-$48.00K	-$120.00K
Free Cash Flow	-$31.30M	-$35.34M	-$53.91M	-$23.11M	-$38.29M	-$25.50M
Depreciation & Amortisation	$825.00K	$2.04M	$2.00K	$23.00K	$28.00K	$36.00K
Stock-Based Compensation	$1.93M	$1.84M	$8.03M	$7.11M	$8.87M	$9.40M
Investing Cash Flow	-$230.00K	$646.00K	-$244.00K	-$48.97M	-$263.24M	-$36.53M
Financing Cash Flow	-$606.00K	$175.06M	$21.55M	$307.80M	$74.87M	-$106.00K
Net Change in Cash	-$31.90M	$140.53M	-$32.36M	$236.02M	-$226.61M	-$62.02M

Market Snapshot

About

Vor Biopharma Inc. is a clinical-stage cell and genome engineering company focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company uses its proprietary platform to enable targeted therapies in combination with stem cell transplants. Vor is working to improve outcomes for patients with blood cancers and solid tumors.